Immunic, INC 10-K annual reports

Immunic, Inc. filed an amendment to its 2025 Annual Report to provide missing corporate governance and executive compensation disclosures.

Immunic, Inc. announced a significant private placement raising $187 million, extending its operational runway while progressing its lead multiple sclerosis and celiac disease drug candidates through clinical trials and securing key intellectual property.

Immunic, Inc. files its 2024 10-K, highlighting clinical progress and financial results, while acknowledging substantial doubt about its ability to continue as a going concern without additional funding.

Immunic, Inc.'s 10-K filing outlines its capital structure, clinical development programs, and financial position, highlighting ongoing trials and recent funding.